ORAMED PHARMACEUTICALS INC.
ORMP evidence brief
What we can confirm
- BioSniper Score:
- 5.3 / 10
- Market Cap:
- $190.7M
- Lead Asset:
- oral insulin (Preclinical)
What it means
What to watch
Prepared research question
What matters most for ORMP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ORMP
ORAMED PHARMACEUTICALS INC. is a biopharmaceutical company developing an oral insulin capsule (ORMD-0801) for Type 2 diabetes and holding strategic investments in healthcare companies such as Alpha Tau and Scilex.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 4 of 6 signals
Market Cap
$190.7M
Cash Runway
—
Lead Asset
oral insulin (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for ORAMED PHARMACEUTICALS INC..
ORAMED PHARMACEUTICALS INC. is a biopharmaceutical company developing an oral insulin capsule (ORMD-0801) for Type 2 diabetes and holding strategic investments in healthcare companies such as Alpha Tau and Scilex.
- Lead pipeline candidate is ORMD-0801, an oral insulin for Type 2 diabetes using POD™ technology, currently in Phase 3 [pipeline].
- Cash and equivalents were $15.2M as of 2026-06-30 [sec].
- Net income was $78.2M as of 2026-06-30 [sec].
- Accumulated losses from inception through December 31, 2025 were approximately $123,436,000 [sec_mda · as of 2026-03-26].
- Company holds strategic investments in Alpha Tau (alpha-radiation oncology platform) and Scilex [sec_mda · as of 2026-03-26].
What works
- ORMD-0801 has advanced to Phase 3 after a subpopulation analysis of prior trials, indicating potential for a refined clinical path [sec_mda · as of 2026-03-26].
- The company’s investment in Alpha Tau has shown encouraging clinical progress, including a 100% local disease control rate in pancreatic cancer trials [sec_mda · as of 2026-05-19].
- Cash position of $15.2M as of 2026-06-30 provides near-term operational runway [sec].
What to weigh
- The company has a history of losses, with an accumulated deficit of approximately $123,436,000 through December 31, 2025 [sec_mda · as of 2026-03-26].
- Future clinical trial results for ORMD-0801 may replicate the failure of prior Phase 3 trials or be inconsistent with earlier data [sec_mda · as of 2026-03-26].
- Additional financing may not be available on acceptable terms, which could force operational reductions or asset divestitures [sec_mda · as of 2026-05-19].
From the filings
Quoted directly from source documents.
ORMD-0801 is in Phase 3 for Type 2 diabetes
“Pipeline Candidate: ormd-0801 Generic Name: oral insulin Indication: Type 2 Diabetes Mellitus Phase: Phase 3”
Accumulated losses through December 31, 2025
“we have incurred losses in an aggregate amount of approximately $123,436,000”
SEC MD&A · March 26, 2026
Alpha Tau's 100% local disease control rate
“100% local disease control rate and favorable safety profile reported in a pooled analysis of its two first-in-human pancreatic adenocarcinoma trials at DDW 2026”
SEC MD&A · May 19, 2026
Catalyst timeline
- 2025-12-15 · Phase 3 start for ORMD-0801 — A double-blinded, placebo-controlled, double-dummy, multi-center randomized Phase 3 study to evaluate efficacy and safety in Type 2 diabetes patients.
Risks & what to watch (3)›
Key risks
- Clinical trial failure risk — Future Phase 3 results may replicate prior failure or be inconsistent with earlier data [sec_mda · as of 2026-03-26]
- Financing uncertainty — Additional financing may not be available on acceptable terms, potentially forcing operational cuts [sec_mda · as of 2026-05-19]
- Accumulated losses — Company has accumulated losses of ~$123.4M through Dec 2025 with no significant product revenue [sec_mda · as of 2026-03-26]
What to watch
- Initiation and results of the revised Phase 3 trial (ORA-D-013-3) for ORMD-0801, expected to be conducted through OraTech [sec_mda · as of 2026-05-19]
- Regulatory progress of Alpha Tau's PMA submission for its pivotal skin cancer trial and FDA dialogue [sec_mda · as of 2026-05-19]
- Company's ability to secure additional financing given capital market conditions [sec_mda · as of 2026-05-19]
Sources: Catalysts · Pipeline · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run ORAMED PHARMACEUTICALS INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ORAMED PHARMACEUTICALS INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income $78M
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
64
Total value held
$44.8M
| Holder | Shares | Value |
|---|---|---|
| bml capital management, llc | 3,167,231 | $10.8M |
| aquamarine financial (cayman) ltd | 2,112,312 | $7.2M |
| mercer global advisors inc /adv | 1,910,540 | $6.5M |
| gem investment advisors, llc | 1,640,069 | $5.6M |
| murchinson ltd. | 1,315,294 | $4.5M |
| boothbay fund management, llc | 600,716 | $2.0M |
| marshall wace, llp | 259,611 | $883K |
| rathbones group plc | 233,018 | $792K |
| dimensional fund advisors lp | 158,209 | $538K |
| wells fargo & company/mn | 157,586 | $536K |
Showing top 10 of 64 institutional holders of ORAMED PHARMACEUTICALS INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 1.7%
- Days to cover
- 5.7
- Shares short
- 576,933
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ORMP short interestGovernance
Frequently asked questions
What is the AI investment thesis for ORAMED PHARMACEUTICALS INC.?
ORAMED PHARMACEUTICALS INC. is a biopharmaceutical company developing an oral insulin capsule (ORMD-0801) for Type 2 diabetes and holding strategic investments in healthcare companies such as Alpha Tau and Scilex.
What is ORAMED PHARMACEUTICALS INC.'s lead drug candidate?
ORAMED PHARMACEUTICALS INC.'s most advanced tracked candidate is oral insulin (Preclinical) for diabetes.
Who is the CEO of ORAMED PHARMACEUTICALS INC.?
Mr. Nadav Kidron Esq. is the chief executive officer of ORAMED PHARMACEUTICALS INC. (ORMP).
Where is ORAMED PHARMACEUTICALS INC. headquartered?
ORAMED PHARMACEUTICALS INC. (ORMP) is headquartered in New York, NY, United States.
What therapeutic areas does ORAMED PHARMACEUTICALS INC. focus on?
ORAMED PHARMACEUTICALS INC. develops therapies across Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.